Methylation of the SREBF1 CpG (cg11851174) plausibly decreased HDL-cholesterol levels (pfdr=4.11 × 10−3) and increased both fasting insulin (pfdr=3.84 × 10−3) and risk of type 2 diabetes (pfdr=2.39 × 10−5; ESM Table 21). Here, SREBF1 is linked to type 2 diabetes mellitus.